Advances in radiotherapy for extensive-stage cell lung cancer
10.3969/j.issn.1000-8179.2019.12.433
- VernacularTitle:广泛期小细胞肺癌放射治疗进展*
- Author:
Siying CHEN
1
;
Jifeng SUN
;
Lujun ZHAO
;
Ping WANG
;
Ningbo LIU
Author Information
1. 天津医科大学肿瘤医院放疗科
- Keywords:
extensive-stage small cell lung cancer(ES-SCLC);
radiotherapy;
prophylactic cranial irradiation (PCI);
immunotherapy
- From:
Chinese Journal of Clinical Oncology
2019;46(12):636-639
- CountryChina
- Language:Chinese
-
Abstract:
Extensive-stage small cell lung cancer (ES-SCLC) accounts for approximately two-thirds of all SCLCs. Chemotherapy is still the main treatment, supplemented with radiotherapy and other comprehensive treatments. Although sensitive to chemotherapy and radiotherapy, almost all ES-SCLCs are vulnerable to treatment resistance and have high recurrence rates. Therefore, novel therapies are needed to improve treatment efficacy. The recent advances in radiotherapy for ES-SCLC include prophylactic cranial irradiation (PCI) and thoracic radiotherapy (TRT). Moreover, immunotherapy has shown good antitumor activity, and immune-checkpoint inhibi-tors may become an important breakthrough in SCLC treatment. This article briefly reviewed the clinical research on radiotherapy and immunotherapy for advanced-stage SCLC.
